Hodgkin lymphoma trials in Netherlands

In Netherlands 10 Also abroad 155

10 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
Where
Amsterdam, Leiden, Maastricht, Rotterdam
Age
18 years and over
People
309 worldwide
Run by
Lakefront Biotherapeutics
See details and how to join2023-510173-34-00 · EU 2023-510173-34-00
Phase 2Taking people
DRUP trial
Where
Alkmaar, Almelo, Amersfoort, Amsterdam, Apeldoorn, Arnhem, Breda, Delft, Deventer, Drachten, Ede Gld, Eindhoven, Gorinchem, Groningen, Heerlen, Hilversum, Hoofddorp, Hoogeveen, Leeuwarden, Leiden, Leidschendam, Maastricht, Nijmegen, Roosendaal, Rotterdam, Schiedam, 's-Gravenhage, Tilburg, Utrecht, Venlo, Zwolle
Age
18 years and over
People
3,000
Run by
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
See details and how to joinNCT02925234 · EU 2023-509152-33-00
Phase 1Taking people
A Trial to Study if REGN5837 in Combination with Odronextamab is Safe for Adult Participants with Aggressive B-cell Non-Hodgkin Lymphomas
Where
Amsterdam, Rotterdam
Age
18 years and over
People
42 worldwide
Run by
Regeneron Pharmaceuticals Inc.
See details and how to joinNCT05685173 · EU 2022-502137-26-00
Phase 3Taking people
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Where
Amsterdam, Delft, Groningen, Leidschendam, Nijmegen
Age
16 years to 69 years
People
1,042 worldwide
Run by
University College, London
See details and how to joinNCT04685616 · EU 2022-500031-37-00
Phase 1/2Taking people
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Where
Utrecht
Age
6 months to 17 years
People
370 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT02332668 · EU 2022-501257-36-00
Phase 3Taking people
A trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressive B-cell Non-Hodgkin Lymphoma.
Where
Hoofddorp, Rotterdam
Age
18 years and over
People
132 worldwide
Run by
Regeneron Pharmaceuticals Inc.
See details and how to joinNCT06230224 · EU 2022-502783-21-00
Phase 2/3Taking people
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Where
Utrecht
Age
Up to 25 years
People
210 worldwide
Run by
University of Birmingham
See details and how to joinNCT05991388 · EU 2024-510575-38-00
Phase 1/2Not yet taking people in Netherlands
The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies
Where
Utrecht
Age
1 year to 45 years
People
18
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT07020260 · EU 2023-507597-40-00
No phaseTaking people
Early Ageing During Therapy in AYA Cancer Patients
Where
Groningen
Age
18 years to 39 years
People
120
Run by
University Medical Center Groningen
See details and how to joinNCT05062707
Phase 1/2Taking people
Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
Where
Amsterdam, Groningen, Maastricht, Nieuwegein, Nijmegen, Rotterdam, 's-Gravenhage, Utrecht, Zwolle
Age
18 years to 64 years
People
37 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT03356054 · EU 2023-510556-22-00